Search Results | MSF Science Portal

Journal Article

|

Research

Sinha A, Klebe R, Rekart ML, Alvarez JL, Skrahina A, et al.

2025-02-18 • Clinical Infectious Diseases

BACKGROUND

Only 63% of patients initiating multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment in 2020 were treated successfully. 24-Wee...

Journal Article

|

Research

Sweeney S, Laurence YV, Berry C, Singh MP, Dodd M, et al.

2025-02-01 • Lancet Global Health

BACKGROUND

New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxaci...

Journal Article

|

Research

Moe S, Azamat I, Allamuratova S, Oluya M, Khristusev A, et al.

2024-09-01 • IJTLD OPEN

BACKGROUND

Dru...

Journal Article

|

Research

Rekart M, Thit P, Oluya M, Moe S, Hasan T, et al.

2024-07-01 • IJTLD OPEN

Background

Isoniazid (INH, H) resistance is the most common drug-resistant TB pattern, with treatment success rates lower than those in drug-susceptible TB. The...

Journal Article

|

Research

Motta I, Cusinato M, Ludman AJ, Lachenal N, Dodd M, et al.

2024-06-06 • Antimicrobial Agents and Chemotherapy

Regimens for the treatment of rifampicin-resistant tuberculosis currently rely on the use of QT-prolonging agents. Using data from the randomized controlled trial, TB-PRACTECAL, we inves...

Journal Article

|

Review

Hasan T, Medcalf E, Nyang'wa BT, Egizi E, Berry C, et al.

2024-03-20 • Clinical Infectious Diseases

BACKGROUND
Effectiveness, safety, tolerability, and adherence are critical considerations in shifting to shorter tuberculosis (TB) regimens. Novel 6-month oral regimens that include ...

Journal Article

|

Research

Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, et al.

2024-02-01 • Lancet Respiratory Medicine

BACKGROUND
Around 500,000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are nee...

Conference Material

|

Video

Stringer B

2023-06-07 • MSF Scientific Day International 2023

Conference Material

|

Slide Presentation

Stringer B, Lowton K, Cusinato M, Fielding K, Liverko I, et al.

2023-06-07 • MSF Scientific Day International 2023

Conference Material

|

Poster

Motta I, Cusinato M, Ludman A, Abdrasuliev T, Butabekov I, et al.

2023-06-07 • MSF Scientific Day International 2023

Conference Material

|

Abstract

Stringer B, Lowton K, Cusinato M, Fielding K, Liverko I, et al.

2023-06-07 • MSF Scientific Day International 2023

INTRODUCTION
The TB-PRACTECAL study trialed a shorter, more tolerable regimen of oral drugs than standard of care (SoC) – which can last for up to 20 months and involve both injectab...

Journal Article

|

Research

Moe S, Rekart ML, Hernandez D, Sholpan A, Ismailov A, et al.

2023-05-01 • International Journal of Tuberculosis and Lung Disease

BACKGROUND:
Bedaquiline (BDQ) is widely used in the treatment of rifampicin-resistant TB (RR-TB). However, resistance to BDQ is now emerging. There are no standardised regimens for ...

Journal Article

|

Research

Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, et al.

2022-12-22 • New England Journal of Medicine

BACKGROUND
In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter, and have a more acceptable side-effect profile than current...

Journal Article

|

Research

Kohler S, Sitali N, Achar J, Paul N

2022-11-23 • Journal of Public Health

BACKGROUND
Tuberculosis (TB) drugs and their import are costly. We assessed how shorter TB drug regimens, which were non-inferior or superior in recent TB trials, can affect the cost...

Journal Article

|

Research

Kohler S, Sitali N, Achar J, Paul N

2022-08-03 • PLOS Global Public Health

Tuberculosis (TB) programs depend on a continuous supply of large amounts of high-quality TB drugs. When TB programs procure TB drugs from international suppliers, such as the Global ...

Journal Article

|

Letter

Bastard M, Bonnet MMB, du Cros PAK, Khamraev AK, Hayrapetyan A, et al.

2015-02-01 • American Journal of Respiratory and Critical Care Medicine

Protocol

|

Research Protocol

Sweeney S, Gomez G, Kitson N, Sinha A, Yatskevich N, et al.

2020-10-10 • BMJ Open

INTRODUCTION
Current treatment regimens for multidrug-resistant tuberculosis (MDR-TB) are long, poorly tolerated and have poor outcomes. Furthermore, the costs of treating MDR-TB are...

Journal Article

|

Research

Bonnet MMB, Sizaire V, Kebede YYK, Janin A, Doshetov D, et al.

2005-10-01 • International Journal of Tuberculosis and Lung Disease

SETTING: After the collapse of the Soviet Union, countries in the region faced a dramatic increase in tuberculosis cases and the emergence of drug resistance. OBJECTIVE: To discuss the r...

Journal Article

|

Research

Gadoev J, Asadov D, Tillashaykhov M, Tayler-Smith K, Isaakidis P, et al.

2015-06-15 • PLOS One

BACKGROUND
TB is one of the main health priorities in Uzbekistan and relatively high rates of unfavorable treatment outcomes have recently been reported. This requires closer analysi...

Journal Article

|

Research

Wharton-Smith A, Horter SCB, Douch E, Gray NSB, James N, et al.

2021-12-04 • Trials

BACKGROUND
Addressing the global burden of multidrug-resistant tuberculosis (MDR-TB) requires identification of shorter, less toxic treatment regimens. Médecins Sans Frontières (MSF)...

Science Portal

The effectiveness and safety of bedaquiline, pretomanid, and linezolid (BPaL)-based regimens for rifampicin-resistant tuberculosis in non-trial settings - A prospective cohort study in Belarus and Uzbekistan

24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation

Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan

A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020

How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial

The safety and tolerability of linezolid in novel short-course regimens containing bedaquiline, pretomanid, and linezolid to treat rifampicin-resistant tuberculosis: An individual patient data meta-analysis

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

Patient-reported experiences and quality of life outcomes in the TB-PRACTECAL clinical trial (PRACTECAL-PRO): a mixed-methods, multi-site study

Patient-reported experiences and quality of life outcomes in the TB-PRACTECAL clinical trial (PRACTECAL-PRO): a mixed-methods, multi-site study

ECG findings in BPaL-based TB treatment regimens: the geographical effect on QT prolongation

Patient-reported experiences and quality of life outcomes in the TB-PRACTECAL clinical trial: PRACTECAL-PRO

Primary bedaquiline resistance in Karakalpakstan, Uzbekistan

A 24-week, all-oral regimen for rifampin-resistant tuberculosis

Costs and import costs of past, present, and future TB drug regimens: a case study for Karakalpakstan, Uzbekistan

The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, Uzbekistan

Revised definitions of multidrug-resistant tuberculosis treatment outcomes: closer to the reality?

Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy

Does One Size Fit All? Drug Resistance and Standard Treatments: Results of Six Tuberculosis Programmes in Former Soviet Countries

Factors associated with unfavorable treatment outcomes in new and previously treated TB patients in Uzbekistan: a five year countrywide study

Optimising recruitment to a late-phase tuberculosis clinical trial: a qualitative study exploring patient and practitioner experiences in Uzbekistan